Athira Pharma GAAP EPS of -$24.70

What: Athira Pharma reported a GAAP EPS of -$24.70, indicating a significant net loss for the period.
Why: The company's net loss is likely due to high research and development expenses, as well as potential setbacks in its clinical trials.
Signal: This negative EPS result may signal a challenging road ahead for the company, potentially impacting investor confidence.
Target: The company's management may need to reassess its financial targets and adjust its strategy to mitigate further losses.
Risk: This significant net loss increases the risk of a potential downgrading of the company's credit rating and a decrease in its stock price.